Novartis increases growth potential through integration of Alcon
- Details
- Category: Novartis
Novartis presented an update on its long-term strategy, performance and vision for continued sustainable growth and gave an in-depth overview on the unique position and business model of the new Alcon Division.
Initiation of Lantus leads to better glycemic control at similar weight gain
- Details
- Category: Sanofi
Sanofi (EURONEXT: SAN and NYSE: SNY) announced data that demonstrates that initiating Lantus® (insulin glargine [rDNA origin] injection) in type 2 diabetes patients leads to better glycemic control and comparable and modest weight gain versus a comparator group consisting of other insulins, oral antidiabetics (OADs) and dietary changes.
Roche named Dow Jones Sustainability Index leader in healthcare for third consecutive year
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) has been recognized as the most sustainable healthcare company globally in the Dow Jones Sustainability Index (DJSI), for the third year in a row. The DJSI World and DJSI Europe Indexes track the performance of the leading sustainability companies based on environmental, social and economic performance.
Bristol-Myers Squibb Completes Acquisition of Amira Pharmaceuticals
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) has completed its previously announced acquisition of privately held Amira Pharmaceuticals, Inc., a small-molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases.
GSK awarded contract by BARDA to support research on potential novel antibiotic
- Details
- Category: GlaxoSmithKline
GSK and the Biomedical Advanced Research and Development Authority (BARDA) have agreed to a contract that will support the development by GSK of a potentially new antibiotic against both hospital Gram negative and biothreat pathogens.
Bayer Confident in Results of ROCKET AF Study
- Details
- Category: Bayer
A Cardiovascular and Renal Drugs Advisory Committee meeting has been scheduled for September 8, 2011, to review the New Drug Application in the USA for rivaroxaban in the prevention of stroke and non-CNS systemic embolism in patients with atrial fibrillation.
Roche’s Tarceva receives European approval for first-line use in a genetically distinct type of lung cancer
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the European Commission has approved Tarceva® (erlotinib) for use in patients with a genetically distinct type of non-small cell lung cancer (NSCLC) in Europe.
More Pharma News ...
- Novartis drug Afinitor® gains EU approval to treat patients with advanced pancreatic neuroendocrine tumors
- AstraZeneca announces top-line results from SATURN study
- Bayer Healthcare to acquire Pathway Medical Technologies
- Daiichi Sankyo & Ranbaxy Announce a New Social Contribution Initiative
- €1 Million Awarded to Winning Projects
- Additional Analyses from PLATO Presented at ESC Congress
- U.S. Food And Drug Administration Approves Pfizer's XALKORI® (crizotinib)